Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Palomar

This article was originally published in The Gray Sheet

Executive Summary

Palomar: Management buy-out of firm's Albuquerque, New Mexico Tissue Technologies skin resurfacing laser subsidiary is announced Dec. 23. Palomar will retain a 15% equity stake in the business and receive warrants to buy an additional 10% stake and a "note receivable." Palomar also will receive royalties on all Tissue Technologies True-Pulse CO2 skin resurfacing lasers sold by the business. Palomar acquired the company, which is to be renamed Tissue Medical Lasers, in May 1996 in a stock swap transaction valued in the $20-30 mil. range ("The Gray Sheet" Feb. 19, 1996, I&W-5). The divestiture, which will help Palomar focus on its core laser-based hair removal business, follows the recent sale for $10 mil. of the firm's non-medical electronics subsidiaries to a management group led by officials of its Dynaco unit ("The Gray Sheet" Dec. 22, In Brief)...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT009376

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel